Construction of a new pharmaceutical plant started in Vorsino Industrial Park

Print 01 June 2017
GMP News

On May 30, Vorsino Industrial Park in the Kaluga region hosted an official ceremony to mark the start of construction of an advanced biopharmaceutical production facility owned by NovaMedica LLC (a RUSNANO investment project).

The key partner of the Russian company in this project is Pfizer that invests in the construction of the plant and transfers to NovaMedica the rights to manufacture and commercialize a portfolio of more than 30 vital drugs (injectable dosage forms), one third of which are currently not manufactured in Russia. The portfolio includes drugs for the treatment of severe bacterial and fungal infections, cardiovascular, inflammatory and oncological diseases.

The production facility will be built in full compliance with international and Russian quality standards which, among other things, will allow to export the manufactured products to international markets. The construction of the plant is scheduled for completion in 2020. The industrial production of first drugs will begin in 2023.

The estimated capacity of the plant is more than 38.5 million units of production (ampoules and vials) per year. The surface area of manufacturing and auxiliary buildings and structures will cover about 23 thousand square meters. The total number of employees will be 250.

Source

Return